TECH

Business Context and Reporting Period

Company: TECHNE Corporation (BIO-TECHNE Corp)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal year ended June 30, 1998

Business Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in the U.S. and R&D Systems Europe Ltd. The company manufactures and sells products for the clinical diagnostics market (hematology controls and calibrators) and the biotechnology research market (cytokines, antibodies, and assay kits). R&D Systems is the world's leading supplier of cytokine-related products to the research community.

Key Financial Metrics

Revenue Composition (Fiscal 1998): Biotechnology Division (56%), R&D Europe (26%), Hematology Division (18%).

Capital Expenditures: $2,955,196 (Fiscal 1998).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10% to $67.3 million, driven by an 18% increase in R&D Systems sales (primarily proteins and antibodies) and increased OEM sales in the Hematology Division. R&D Europe sales decreased 6% due to the discontinuance of the molecular biology product line, though continuing product lines grew 22%.
• Profitability: Net earnings increased 39% to $15.2 million. Gross margins improved to 70.3% due to favorable product mix changes and increased production volumes in both Biotechnology and Hematology divisions.
• Acquisitions: On July 1, 1998 (post-fiscal year end), the company acquired Genzyme Corporation's research products business for approximately $41.76 million (cash, stock, and royalties). This establishes R&D Systems as the world's leading supplier of research and diagnostic cytokine products.
• Investments: The company invested $2 million in ChemoCentryx, Inc. (CCX) for a 28% interest and exclusive research/diagnostic rights to chemokine products. CCX is consolidated into financial statements.
• Expense Management: R&D expenses decreased by $1.06 million, largely due to reduced payments under a joint research agreement with British Bio-technology Group plc.

Guidance, Outlook, and Risks

• Earnings Guidance: Management anticipates fiscal 1999 earnings will be $0.06 to $0.12 per share lower than fiscal 1998. This is primarily due to the sale of acquired Genzyme inventories at lower gross profit levels and the amortization of goodwill associated with the transaction.
• Capital Needs: The company expects to fund future operations and capital additions (estimated at $4 million for fiscal 1999) through existing cash, operating cash flow, and short-term investment maturities. No long-term debt is outstanding.
• Legal Proceedings: The company is involved in patent litigation with Streck Laboratories, Inc., alleging infringement of three patents related to white blood cell hematology controls. The case is in discovery and unlikely to go to trial before 1999.
• Key Risks:
  • Technological Obsolescence: Rapid changes in biotechnology and hematology instrumentation could render current products obsolete.
  • Patent Infringement: The company has not conducted a patent infringement study for every product and faces potential litigation or licensing costs.
  • Regulatory Approval: Delays in FDA or other regulatory approvals for new diagnostic kits could adversely affect revenue.
  • Year 2000 Compliance: The company is upgrading systems to ensure Y2K compliance by mid-1999; costs are not expected to be material.

Investor Verification Checklist

• Genzyme Acquisition Integration: Verify the success of converting Genzyme customers and distributors to TECHNE products, as this is critical to offsetting the anticipated earnings dilution in fiscal 1999.
• ChemoCentryx Milestones: Monitor the achievement of milestones by ChemoCentryx, Inc., which could trigger an additional $3 million investment obligation by TECHNE.
• Patent Litigation Outcome: Track the status of the lawsuit with Streck Laboratories, as an adverse ruling could impact the Hematology Division's revenue stream.
• European Operations: Confirm the stability of R&D Europe's margins, which decreased from 52.5% to 47.5% in fiscal 1998 due to product mix and exchange rates.
• Stock Repurchase Program: Note that the company has a plan to repurchase up to $10 million of common stock; verify the pace of buybacks against cash flow generation.